BTC Network, a fully integrated network of clinical research sites in the U.S., has strengthened its site operations with the recent acquisition of Novex Clinical Research, a multi-specialty research practice in New Bedford, Massachusetts. As a result of the deal, Novex Clinical Research will be the first clinical research site to be owned and operated under the BTC Network umbrella. It will strengthen BTC Network’s expertise and commitment to therapeutic areas such as psychiatry, neurology, pain, and internal medicine.

Novex Clinical Research has proven its clinical trial expertise with its board-certified physician investigators and professional research coordinators that have managed nearly 300 clinical studies. Novex, as a top enroller and one of the premier industry leaders in psychiatry, neurology and pain, provides BTC Network with a great opportunity to strengthen its access to relevant studies. Novex Clinical Research will now be known as BTC of New Bedford.

Since announcing a rebranding ahead of the DIA conference in Philadelphia in June 2016, BTC Network has been quickly growing its owned and affiliated site model across the U.S. The company, which until recently was known as BlueTheory Clinical Trials, has been experiencing significant growth through its integrated site network or PRIME Network Model, which provides exclusive relationships and centralized processes at a growing number of facilities across the U.S. The acquisition of Novex allows BTC Network to offer customers access to over ten thousand potential patients within relevant therapeutic areas.

Scott Palmese, BTC Network’s director of Clinical Operations, said, “Novex Clinical Research shares BTC Network’s progressive views and, by combining, we can enhance our ability to scale our know-how, infrastructure, and healthcare relationships to bring more of the right trials to the right patients. Together we will enhance the execution of clinical trials and deliver greater value for both the industry and health care systems, forging better and closer connections. The ultimate beneficiary of this work will be patients, through lower cost of care, improved clinical outcomes, and enhanced patient experiences.”

Christian Burns, vice president of BTC Network and president of ClinEdge (sister company to BTC Network), stated, “BTC Network already has a strong footprint in the U.S. This latest acquisition is important as it marks BTC Network’s entry into the site ownership space, giving us a diverse range of therapeutic capabilities and services for our sponsor and CRO clients. Novex Clinical Research’s reputation, commitment to patients, and diverse range of experience aligns nicely with our organization’s future goals.”